T he hallmark of allosteric proteins is that they exist in multiple conformations in equilibrium.
1,2 When alternative conformations differ in their functional properties, linkage is established between structure and biological activity and allostery becomes the basis of the effects observed experimentally. The theoretical underpinnings of allosteric transitions have been defined for systems working at equilibrium 1 or under transient kinetics. 3 Yet structural validation of a preexisting equilibrium between alternative conformations remains a challenge even for textbook examples of allosteric proteins. 2, 4 Allostery is not an exclusive property of multimeric proteins. Indeed, the ability of monomeric enzymes to express complex behavior consistent with allosteric transitions has long been recognized. 3, 5 Trypsin-like proteases are monomeric enzymes which constitute the largest and best studied group of homologous proteases in the human genome. 6 They are phylogenetically grouped into six functional categories: digestion, coagulation and immunity, tryptase, matriptase, kallikrein, and granzymes. Trypsin-like proteases share a common mechanism of catalysis that relies upon the coordinate action of three catalytic residues: H57, D102, and S195 (chymotrypsinogen numbering). In addition, they share a common mechanism of activation: an inactive zymogen precursor is proteolytically cut between residues 15 and 16 to generate a new N-terminus that ion-pairs with the highly conserved D194 next to the catalytic S195 and organizes both the oxyanion hole and primary specificity pocket.
6À8
The irreversible zymogenfprotease conversion affords a useful paradigm to explain the onset of catalytic activity as seen in the digestive system, blood coagulation, or the complement system and is particularly useful to understand the initiation, progression, and amplification of enzyme cascades, where each component acts as a substrate in the inactive zymogen form in one step and as an active enzyme in the subsequent step. 9 However, considerable variation in catalytic activity is observed among members of the trypsin family following conversion from the inactive zymogen form. Digestive enzymes such as trypsin, chymotrypsin, and elastase complement factors C1r and C1s, and coagulation factors like thrombin are highly active after the zymogenfprotease conversion has taken place. On the other hand, complement factors B and C2 are mostly inactive until binding of complement factors C3b and C4b enable catalytic activity at the site where amplification of C3 activation leads to formation of the membrane attack complex.
10À12 Coagulation factor VIIa circulates in the blood as a poorly active protease that acquires full catalytic competence only upon interaction with tissue factor that becomes exposed to the bloodstream upon vascular injury. 13, 14 Complement factor D assumes an inactive conformation with a distorted catalytic triad 15, 16 until binding to C3b and factor B promote substrate binding and catalytic Biochemistry ACCELERATED PUBLICATION activity. 17, 18 The high catalytic activity of trypsin, C1r, and thrombin and the ability of complement factor D or coagulation factor VIIa to remain in a zymogen-like form suggest that the trypsin fold may assume active and inactive conformations even after the zymogenfprotease conversion has taken place. Existence of an allosteric equilibrium between active and inactive forms has been proposed for coagulation factor VIIa. 14, 19 Rapid kinetics support a pre-existing equilibrium between active (E) and inactive (E*) forms for thrombin, 20, 21 meizothrombin desF1, 22 factor Xa, and activated protein C. 23 Structures of thrombin in the free form reveal a conformation, E, with the active site open 24À26 and an alternative conformation, E*, with the active site blocked by repositioning of the 215À217 segment. 27À30 However, no evidence currently exists that the same protease construct may assume alternative conformations that can be trapped by crystallographic analysis. This evidence is reported here for the first time.
' MATERIALS AND METHODS
Thrombin mutants N143P and Y225P were expressed in mammalian cells or E. coli and purified to homogeneity as described previously. 29, 31 Crystallization was achieved at 22°C using the hanging drop vapor diffusion method, with each reservoir containing 500 μL of solution. Equal volumes (2 μL) of the protein sample (8À9 mg/mL) and reservoir solution (see Table 1 ) were mixed to prepare the hanging drops. Diffraction quality crystals grew in two weeks and were frozen using 15%À25% glycerol as cryoprotectant at 100 K. X-ray diffraction data were collected to 1.9À2.1 Å with a home source (Rigaku 1.2 kW MMX007 generator with VHF optics) Rigaku Raxis IV ++ detector and were indexed, integrated, and scaled with the HKL2000 software package. 32 Structures were solved by molecular replacement using MOLREP from the CCP4 suite 33 and using as search models PDB accession code 3JZ1 for N143P in the E form, 1SHH for Y225P in the E form, and 3BEI for Y225P in the E* form. Refinement and electron density generation were performed with REFMAC 34 from the CCP4 suite, and 5% of the reflections were randomly selected as a test set for cross-validation. Model building was performed in COOT. 35 In the final stage of refinement, TLS tensors modeling rigid-body anisotropic temperature factors were calculated and applied to the model. Ramachandran plots were calculated using PROCHECK. 36 Statistics for data collection and refinement are summarized in Table 1 . Atomic coordinates and structure factors have been deposited in the PDB as 3QGN (N143P E form), 3S7K (Y225P E form), and 3S7H (Y225P E* form).
Stopped-flow fluorescence measurements of PABA binding to thrombin were performed over a time range of 100 ms using an Applied Photophysics SX20 spectrometer. An excitation wavelength of 330 nm and a cutoff filter of 375 nm were used for the experiments. All experiments were carried out in buffer containing 50 mM Tris, 0.1% PEG8000, pH 8.0 at 15°C. Thrombin wild type or mutant at a final concentration of 1 μM was mixed 1:1 with increasing concentrations of PABA, having first established a baseline by mixing buffer and the same concentration of PABA. Applied Photophysics Pro-Data software was used to fit single exponential curves to the average of six or more kinetic traces for each PABA concentration. PABA was found to obey a two-step binding mechanism, with a fast phase too rapid to resolve and a slow, single exponential phase whose k obs decreases with increasing [PABA] . This dependence of the slow phase on ligand concentration is unequivocal proof of the kinetic mechanism of binding
which is analogous to the binding mechanism of Na + . A preequilibrium between two forms, E* and E, precedes PABA (L) binding that can only occur to the active form E. The total fluorescence change observed upon PABA binding obeys the expression 
is the apparent PABA binding affinity that depends on the intrinsic PABA binding affinity
and the equilibrium constant for the E*ÀE interconversion r
Under conditions of separation of time scales, where PABA binding and dissociation are faster than the rates for the E*ÀE interconversion, the k obs for the evolution of the slow phase of fluorescence increase upon PABA binding obeys the expression
The value of k obs decreases hyperbolically with increasing
, thereby yielding k r , k Àr , and K A .
' RESULTS AND DISCUSSION
Structures of thrombin in the free form reveal a conformation with the active site fully accessible to substrate 24À26 and an alternative conformation with the active site blocked by repositioning of the W215 side chain and entire 215À217 segment. 27À30 Although these conformations provide a structural basis for the allosteric E*ÀE equilibrium identified by kinetic studies, 20, 21, 23 they have been documented with different protease constructs. The mutant N143P was engineered to abrogate the H-bond between the carbonyl O atom of E192 and the backbone N-atom of N143, resulting in a flip of the E192-G193 peptide bond and disruption of the oxyanion hole formed by the backbone N-atoms of G193 and S195. 29 A recently published structure of N143P in the free form reveals the predicted disruption of the oxyanion hole and a collapsed architecture of the active site (Figure 1) as observed in the E* form of the thrombin mutants D102N 28, 30 and Δ146À149e.
27
The new structure of N143P in the free form reveals an open conformation of the active site (Figure 1 ), consistent with that observed in the E form of mutants R77aA 25 and Figure 1 . X-ray crystal structures of the thrombin mutants N143P and Y225P in the E* and E forms. Ribbon representation of the structure of the thrombin mutants N143P (A) and Y225P (B) in the E (cyan) and E* (gold) forms. In the E* form the side chain of W215 and the entire 215À217 segment collapse into the active site (red arrow). In the E form, W215 moves back 10.9 Å and the 215À217 segment moves 6.6 Å to make the active site accessible to substrate. The rmsd between the two forms is 0.328 Å (N143P) or 0.345 Å (Y225P). Relevant residues are labeled and rendered as sticks.
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C191A/C220A. 24 The side chain of W215 moves back >10 Å toward F227 and relinquishes its interaction with the catalytic H57. The entire 215À217 segment moves >6 Å and opens up access to the active site. The mutant Y225P was engineered to abolish Na + binding and constitutively stabilize thrombin in the Na + -free slow form. 37, 38 Residue 225 has a dichotomous distribution in trypsin-like proteases: Pro is the preferred residue at this position, but Na + binding requires the presence of Tyr or Phe as seen in clotting and complement proteases. The slow form is the form of thrombin free of any ligands, and based on the results of rapid kinetics, it is a mixture of the inactive E* and active E forms. The mutant was crystallized previously bound to an active site inhibitor. 39 The new structures of Y225P in the free form reveal the two conformations, E and E*, analogous to those documented for N143P (Figure 1) , thereby confirming that free thrombin (or slow thrombin) is a mixture of E* and E in allosteric equilibrium as predicted by kinetic studies on the wild-type, 20 The E*ÀE equilibrium was originally discovered from rapid kinetic studies of Na + binding to thrombin, 20 recently extended to meizothrombin desF1, 22 activated protein C, and factor Xa. 23 Because Na + cannot bind to the mutant Y225P due to the shift in the carbonyl O-atom of K224 caused by the presence of P225, 37 an alternative probe of the E*ÀE equilibrium becomes necessary. Such a probe could have wide applicability to trypsin-like proteases in general because Pro is the residue most represented at the 225 position in these enzymes 40 and Na + activation is present only in a minority of enzymes in blood coagulation and the complement cascade. 41 The active site inhibitor PABA has long been known as a useful reagent in fluorescence studies 42 and turned out to be an excellent probe of the accessibility of the active site in the E and E* forms (Figure 2 ). Rapid kinetics of PABA binding to wild-type thrombin reveals a two-step mechanism analogous to that observed for Na + binding, with a fast phase completed within the dead time of the instrument and a slow phase of exponential increase in fluorescence whose k obs decreases hyperbolically as a function of [PABA] (Figure 2 ). This is an unequivocal signature of the existence of a pre-equilibrium that precedes PABA binding to the enzyme, and it likely reports the same E*ÀE equilibrium detected from Na + binding measurements. Indeed, the rate constants for the E*ÀE interconversion derived from measurements of PABA binding (Table 2 ) are comparable to those derived from Na + binding. Hence, the E*ÀE equilibrium in solution can be probed independently by binding to two different domains of the enzyme, the Na + site or the active site. Rapid kinetic measurements of PABA binding to the mutants N143P and Y225P also reveal a slow phase with a k obs decreasing hyperbolically with increasing [PABA], thereby enabling detection of the E*ÀE equilibrium in systems where either Na + cannot bind to its site (Y225P) or Na + binding does not elicit a slow kinetic phase (N143P). 29 This offers a powerful new strategy to probe the E*ÀE equilibrium in other trypsin-like proteases.
The relevance of these findings carries over to the entire family of trypsin-like proteases to which thrombin belongs. Indeed, a recent analysis of the entire structural database demonstrates that the E*ÀE equilibrium is a general feature of the trypsin fold, made possible by the conformational flexibility of W215 and the 215À217 segment. 43 The E* form has been observed in the thrombin mutants D102N, 28, 30 Δ146À149e, 27 N143P, 29 and Y225P reported here, complement factor D wild-type and mutants S915A, S215W, and R218A, 16À18 prostate specific antigen, 44 tonin, 45 prophenoloxidase activating factor II, 46 hepatocyte growth factor activator, 47 and prostasin. 48, 49 The E form has been observed in the thrombin mutants R77aA, 25, 26 C191A/ C220A, 24 and N143P and Y225P reported here, complement factors C1r 50 and C2a, 51, 52 neuropsin, 53 and trypsin. 54 Mutant D216G of RI-tryptase crystallizes with the 215À217 segment in two conformations in a 3:1 occupancy ratio:
55 one open and the Table 2 a From the data in Figure 3AÀC using eq 1 in the text. b From the data in Figure 2D using other collapsed as in the wild-type. 56 Relevant examples of these proteases in the E and E* forms are given in Figure 3 . Detection of E* and E for the same protease construct remains challenging because it requires crystallization of the free form under conditions where either E* or E can be trapped. However, this difficulty can be overcome, as shown by the thrombin mutants N143P and Y225P reported here, and we expect more trypsin-like proteases to be crystallized in both the E* and E forms in the near future.
The physiological relevance of the E*ÀE equilibrium deserves attention. When E* is stabilized, the protease possesses low activity and acts as a switch that can be turned on by binding of specific cofactors or allosteric activators that facilitate conversion to the active E form. Relevant examples are complement factor D that shifts from the E* to the E form upon binding to the complex of C3b and factor B 17 and coagulation factor VIIa that makes a similar transition upon binding to tissue factor. 14, 19 Stabilization of E produces a highly active enzyme upon conversion from the zymogen form without requiring macromolecular cofactors, as seen in trypsin, complement factor C1r, and thrombin. Therefore, the E*ÀE equilibrium provides a reversible mechanism of regulation of enzyme activity following the irreversible transition from the zymogen form. The repertoire of activities available to the protease is greatly expanded in ways that fit the diverse requirements of enzymes acting in different biological environments or at different levels of cascades like blood coagulation and the complement. 
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